PROK vs. ALEC, VALN, ALLO, HUMA, VYGR, CCCC, EDIT, TSHA, ADPT, and ITOS
Should you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Alector (ALEC), Valneva (VALN), Allogene Therapeutics (ALLO), Humacyte (HUMA), Voyager Therapeutics (VYGR), C4 Therapeutics (CCCC), Editas Medicine (EDIT), Taysha Gene Therapies (TSHA), Adaptive Biotechnologies (ADPT), and iTeos Therapeutics (ITOS). These companies are all part of the "biological products, except diagnostic" industry.
Alector (NASDAQ:ALEC) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings.
ProKidney has lower revenue, but higher earnings than Alector. ProKidney is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.
Alector received 140 more outperform votes than ProKidney when rated by MarketBeat users. However, 66.67% of users gave ProKidney an outperform vote while only 60.58% of users gave Alector an outperform vote.
ProKidney has a net margin of 0.00% compared to ProKidney's net margin of -125.11%. Alector's return on equity of 0.00% beat ProKidney's return on equity.
Alector presently has a consensus target price of $14.00, indicating a potential upside of 166.67%. ProKidney has a consensus target price of $9.50, indicating a potential upside of 238.08%. Given Alector's higher probable upside, analysts clearly believe ProKidney is more favorable than Alector.
Alector has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.
In the previous week, Alector had 7 more articles in the media than ProKidney. MarketBeat recorded 14 mentions for Alector and 7 mentions for ProKidney. Alector's average media sentiment score of 0.95 beat ProKidney's score of 0.41 indicating that ProKidney is being referred to more favorably in the news media.
85.8% of Alector shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 14.0% of Alector shares are owned by insiders. Comparatively, 45.0% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
ProKidney beats Alector on 9 of the 17 factors compared between the two stocks.
Get ProKidney News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProKidney Competitors List
Related Companies and Tools
